<DOC>
	<DOCNO>NCT01911624</DOCNO>
	<brief_summary>Safety efficacy direct thrombin inhibitor versus enoxaparin patient staphylococcus aureus bacteraemia . The study hypothesize inhibition coagulase-activity S. aureus direct thrombin inhibitor safe translates well outcome patient S. aureus bacteremia .</brief_summary>
	<brief_title>Direct Thrombin Inhibitors Versus LMWH Staphylococcus Aureus Bacteraemia</brief_title>
	<detailed_description>Single center randomize controlled trial direct thrombin inhibitor versus standard enoxaparin . - Feasibility : proportion patient eligible randomization ; clinically attain concentration DTI result staphylothrombin inhibition - Safety : bleeding event ( major/ clinically relevant non-major ) - Efficacy : thrombotic event thromboprophylactic treatment + 3 day - Secondary outcome measure - Coagulation parameter : evolution D-dimers day 0-4 ; lab parameter coagulation ( PT/APTT/fibrinogen/platelet count ) - Inflammatory parameter : CRP , white blood cell count , neutrophilia - Clinical outcome : metastatic infection , assess clinically PET/CT ; relapse S. aureus bacteremia ; defervescence ; persistent positive blood culture ; hospital stay , mortality .</detailed_description>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Argatroban</mesh_term>
	<mesh_term>Antithrombins</mesh_term>
	<criteria>Positive blood culture staphylococcus aureus Symptoms sign infection Indication thromboprophylaxis Contraindication thromboprophylaxis Significant active bleeding risk excessive bleeding Heparininduced thrombocytopenia Severe liver kidney disease Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>